{"id":"NCT04343287","sponsor":"BRIM Biotechnology Inc.","briefTitle":"Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment","officialTitle":"A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAEÂ®) Model","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-01-15","primaryCompletion":"2020-06-23","completion":"2020-06-23","firstPosted":"2020-04-13","resultsPosted":"2021-10-21","lastUpdate":"2021-10-21"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DRUG","name":"BRM421","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BRM421 Ophthalmic Solution","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.","primaryOutcome":{"measure":"Ocular Sign: Change From Baseline in Total Corneal Staining Score to Day 14","timeFrame":"2 weeks","effectByArm":[{"arm":"BRM421 Ophthalmic Solution","deltaMin":-1,"sd":1.245},{"arm":"Placebo","deltaMin":-0.68,"sd":1.392}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":108},"commonTop":["instillation site pain"]}}